Veracyte公司宣布,其与Enzamet试验合作获得的数据显示,Decipher前列腺基因组分类检测能够有效识别出哪些转移性前列腺癌患者可能从化疗中获益。这一发现为临床精准治疗决策提供了重要依据,有望帮助医生更准确地筛选适合接受强化化疗的患者群体,从而优化治疗策略并改善患者预后。
Veracyte公司宣布,其与Enzamet试验合作获得的数据显示,Decipher前列腺基因组分类检测能够有效识别出哪些转移性前列腺癌患者可能从化疗中获益。这一发现为临床精准治疗决策提供了重要依据,有望帮助医生更准确地筛选适合接受强化化疗的患者群体,从而优化治疗策略并改善患者预后。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.